Recombinant Horse EPO/Erythropoietin Protein Protein (Baculovirus)，His & Myc

Erythropoietin (EPO) is a glycoprotein hormone primarily produced by the kidneys that plays a crucial role in the regulation of red blood cell production in response to hypoxia. Its recombinant form, rhEPO, has been widely studied and utilized in clinical settings to treat conditions such as anemia, particularly in patients with chronic kidney disease, cancer, or those undergoing chemotherapy. The recombinant production of EPO has revolutionized therapeutic approaches, enabling higher purity and reduced risk of contamination that was often observed with urine-derived EPO. Research into rhEPO has not only elucidated its structure and mechanisms of action but has also expanded its applications beyond anemia treatment, exploring potential benefits in areas such as tissue protection in ischemic conditions and performance enhancement in sports, although the latter has raised ethical concerns regarding doping. The advancements in biotechnological methods, such as genetic engineering in mammalian cell systems, have led to the efficient production of EPO with desired pharmacokinetic properties, making it a key focus of ongoing research in regenerative medicine and hematology. Overall, the study of recombinant EPO continues to offer insights into erythropoiesis and novel therapeutic strategies for various hematological disorders.